FORRESTER
30.4.2024 10:01:35 CEST | Business Wire | Press release
Forrester (Nasdaq: FORR) today announced the full conference agenda for its CX Summit EMEA event being held in London and digitally on June 24-26, 2024. Today, customers expect more personalised services that reflect their unique preferences and behaviours. With the advances in AI, companies now have an opportunity to integrate generative AI (genAI) tools with human capabilities to deliver more intuitive and responsive customer experiences (CX) that foster loyalty and satisfaction. However, the socioeconomic and cultural differences in Europe, combined with new AI regulations, pose a challenge, requiring a deep understanding of how to effectively integrate human and AI experiences, while managing the new and complex regulatory landscape.
Featuring immersive experiences, keynote presentations, case studies, and dedicated breakout sessions, CX Summit EMEA will offer the latest research and frameworks to help CX, digital, and B2C marketing leaders understand how AI will transform customer and business interactions in the future.
Noteworthy sessions include:
- Solve The AI Customer’s Dilemma: To Be Or Not To Be. This keynote session outlines the emerging AI rules and requirements, and what companies must do to build trust and succeed in an AI-driven future.
- How CX Teams Can Unlock The GenAI Promise. In this session, CX leaders will learn how to anticipate the changes genAI will bring to their teams.
- Key Steps To A Successful Talent Strategy In The Age Of AI. This keynote will share why talent acquisition is breaking under the strain of AI-enabled applicants and the tools needed to succeed in a talent-restrained world.
- Ignore The Hype And Focus On How You Get The Most Out Of (Gen)AI. This session reveals how to avoid the most common pitfalls and anticipate the key actions needed to succeed with genAI.
- Sustainability Now, Not Later: AI Will Supercharge The Green Market Revolution. In this session, understand how to apply AI to scale environmental sustainability use cases.
- Align CX, Digital, And Tech With Metrics That Matter. This session discusses what CX metrics companies must use to foster internal alignment.
CX Summit EMEA will also honour the recipient of Forrester’s 2024 Customer-Obsessed Enterprise Award - EMEA, which recognises companies that drive business success by putting customers at the centre of their leadership strategy and operations. In addition, attendees can experience Forrester’s CX certification course, participate in Forrester’s Women’s Leadership Program and take part in the GenAI Hackathon, an interactive networking session that will explore the strengths and weaknesses of AI tools. Senior leaders can attend an invitation-only executive programme, the Executive Leadership Exchange, to expand on the Forrester thought leadership presented at the conference and discuss best practices aligned to executive priorities.
“The integration of AI tools and human capabilities is the future of customer experience; however, with new AI legislation on the horizon, leaders in Europe are navigating in unchartered waters,” said Martin Gill, VP and research director at Forrester. “CX Summit EMEA will help CX, marketing and digital leaders understand the impact these new regulations will have on their business and how they can successfully integrate AI into their CX strategies to meet customers’ changing needs — now and in the future.”
Resources:
- Register to attend Forrester’s CX EMEA event.
- View the full agenda and speakers for CX EMEA.
- Members of the press interested in attending, please contact press@forrester.com.
- Check out the Forrester Decisions services for Customer Experience, B2C Marketing Executives, and Digital Business & Strategy.
- Follow @Forrester and #ForrCX for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430394678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
